IMMUNOVIA AB news, videos and press releases - Page 4
For more news please use our advanced search feature.
IMMUNOVIA AB - More news...
IMMUNOVIA AB - More news...
- Immunovia publishes the annual report for 2022
- Immunovia publishes the annual report for 2022
- Immunovia to participate in National Pancreas Foundation Webinar on Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer
- Immunovia announces outcome of the rights issue
- Immunovia publishes prospectus relating to the rights issue
- Bulletin from the extraordinary general meeting in Immunovia AB
- Immunovia appoints Karl Stone as new chief operating officer to develop R&D and operations
- Immunovia Publishes Full Year Report for 2022
- Immunovia Publishes Full Year Report for 2022
- Invitation to Immunovia's Q4 presentation
- Invitation to Immunovia's Q4 presentation
- CONVENING NOTICE - EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (publ)
- CONVENING NOTICE - EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (publ)
- Immunovia resolves on a rights issue of approximately SEK 202.2 million and postpones the publication of the quarterly report for the first quarter and the annual general meeting
- Immunovia - Consultation process with Swedish unions completed
- Immunovia announces updated financial calendar for financial year 2023
- Immunovia announces updated financial calendar for financial year 2023
- Immunovia realigning Swedish operations with strategic priorities and its focus on the US commercialization of the IMMray™ PanCan-d test
- Immunovia realigning Swedish operations with strategic priorities and its focus on the US commercialization of the IMMray™ PanCan-d test
- Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray™ PanCan-d test in the US market
- Immunovia strengthens US organization to continue commercialization of its novel IMMray™ PanCan-d test
- Centers for Medicare & Medicaid Services finalizes its payment determination and sets a rate of $897 for Immunovia's IMMray PanCan-d test
- Chief Executive Offier, Philipp Mathieu, buys Immunovia warrants
- Chief Executive Offier, Philipp Mathieu, buys Immunovia warrants
- Immunovia announces the financial calendar for financial year 2023
- Immunovia announces the financial calendar for financial year 2023
- Immunovia Publishes Interim Report Jan-Sep 2022
- Immunovia Publishes Interim Report Jan-Sep 2022
- Invitation to Immunovia's Q3 presentation
- Invitation to Immunovia's Q3 presentation
